STOCKS TELEGRAPH

Tag: FUSN Stock Price

  • Fusion Pharmaceuticals (FUSN) Soars On Merger Announcement

    Fusion Pharmaceuticals (FUSN) Soars On Merger Announcement

    The current trading session witnesses a noteworthy ascent in the stock value of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), surging by 97.32% to $21.00 at the latest market check. The disclosure of an important merger deal is strongly related to the recent spike in FUSN’s stock price.

    Fusion Pharmaceuticals (FUSN) has taken a significant step forward announcing their intention to be bought by AstraZeneca. This purchase demonstrates AstraZeneca’s dedication to transforming cancer treatment techniques, with the goal of replacing traditional treatments like radiation and chemotherapy with more focused strategies and improving patient results.

    In recent years, radioconjugates (RCs) have become a potential new area in cancer therapy. Through the use of substances such as antibodies, peptides, or tiny molecules, these therapeutic treatments precisely transport radioactive isotopes to cancer cells. This precision-based approach offers several potential advantages over traditional radiotherapy, particularly in minimizing harm to healthy tissues and accessing previously inaccessible tumors through external beam radiation.

    AstraZeneca’s acquisition of Fusion complements its already robust oncology portfolio, notably enriching it with Fusion’s pipeline of RCs. Among these, FPI-2265 emerges as a promising novel therapy for metastatic castration-resistant prostate cancer (mCRPC). Currently in Phase 2 clinical trials, FPI-2265 targets prostate-specific membrane antigen (PSMA), a protein excessively expressed in mCRPC.

    Integration of Fusion into its operations also grants AstraZeneca fresh expertise in actinium-based RCs, alongside advanced capabilities in research and development, manufacturing, and supply chain management. Furthermore, this acquisition underscores AstraZeneca’s commitment to and deepening involvement in Canada.

    Following the acquisition, Fusion will persist in operating in both Canada and the United States as a wholly owned subsidiary of AstraZeneca. As per the final agreement, AstraZeneca will acquire all outstanding shares of Fusion through a plan of arrangement, tendering $21.00 in cash upon closure, alongside a nontransferable contingent value right (CVR) of $3.00 in cash contingent upon meeting specific regulatory milestones.

    The subsidiary will execute this acquisition of Fusion’s shares. A notable 97% premium was disbursed over Fusion’s closing market price on March 18, 2024, and an 85% premium over Fusion’s volume-weighted average price (VWAP) of $11.37 before this announcement. The transaction is estimated to be valued at $2 billion in cash.

  • Extended-Session Rise In Fusion Pharmaceuticals (FUSN) Stock

    Extended-Session Rise In Fusion Pharmaceuticals (FUSN) Stock

    During Thursday’s extended session, Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) had a 7.94% increase in stock price, closing at $9.11. That carried over the regular session’s 6.84% rise to close at $8.44. With the company’s announcement of clinical programs and sharing of production information the previous day, the spike in FUSN shares persisted.

    Fusion Pharmaceuticals (FUSN) reported substantial advancements with its FPI-2265 research program and the first clinical doses produced at its own manufacturing facility. FUSN is off to a strong start in 2024 with a promising registration-enabling path for FPI-2265 and positive program outcomes for FPI-1434.

    In addition to the early signs of anticancer activity, a fully operational TAT manufacturing facility has begun producing clinical doses for the actinium-based PSMA lead study. FUSN successfully synchronized a protocol and development plan for FPI-2265 with the Food and Drug Administration (FDA) of the United States.

    If authorized, it would give the FUSN team a possible route to registration and place FPI-2265 as the first actinium-based PSMA targeting radioligand treatment on the market. Patients who progress on or after lutetium-based therapy will likely have a major unmet need that FPI-2265 will likely address given the rapidly expanding market for PLUVICTO.

    The revised development strategy calls for the completion of enrollment in a Phase 2 dosage optimization lead-in by the end of 2024, as well as the start of a Phase 3 registrational study in 2025. It is anticipated that the Phase 2 study will begin in 2024’s second quarter and that enrollment will be finished by the end of the year.

    In order to ascertain the suggested Phase 3 dosage schedule based on examination of the Phase 2 data, the Company will attempt to schedule an End of Phase 2 meeting with the FDA. FUSN also manufactured the first clinical dosage of a TAT and finished validating its cutting edge good manufacturing practice (GMP) production facility.

    Fusion’s facility, which can manufacture TATs on a clinical and commercial scale, is intended to support the company’s expanding TAT pipeline and has the capacity to produce up to 100,000 doses annually.

  • Fusion Pharmaceuticals (FUSN): What Caused After-Hour Surge

    Fusion Pharmaceuticals (FUSN): What Caused After-Hour Surge

    Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) witnessed a substantial surge in its stock value during Friday’s after-market trading session, further augmenting gains achieved in the regular session. The shares of Fusion Pharmaceuticals experienced a noteworthy increase of 7.16% during the extended trading hours, reaching $4.34, following a 1.25% upswing in the regular session, closing at $4.05.

    The impetus for this upward trajectory can be attributed to the company’s participation in an investor conference and the extension of a collaborative agreement. A fireside chat presentation conducted by Fusion Pharmaceuticals (FUSN) occurred on Thursday at the Jefferies London Healthcare Conference. Dr. John Valliant, the Chief Executive Officer of FUSN, eloquently represented the company during this event.

    Furthermore, Fusion Pharmaceuticals solidified a fresh agreement with BWXT Medical Ltd., a subsidiary of BWX Technologies. This agreement pertains to the supply of generators essential for the production of actinium-225, a medical isotope utilized in cancer treatment clinical trials. Under the terms of the agreement, BWXT Medical will furnish Fusion Pharmaceuticals with a preferential supply of radium-225 and access to generator technology.

    This strategic collaboration empowers FUSN to manufacture actinium-225 on-site at its Good Manufacturing Practice (GMP) facility. Additionally, the companies have expanded their existing agreement for the supply of actinium-225, reinforcing Fusion’s progressive pipeline of targeted alpha therapies.

    Actinium-225, an alpha-emitting isotope integral to Fusion’s targeted alpha therapies (TATs), is combined with specific tumor-targeting vectors to eradicate cancer cells while minimizing harm to healthy tissues. Radium-225 serves as the parent isotope, undergoing decay to produce actinium-225.The proprietary generator technology from BWXT enables the on-demand isolation of high-purity actinium-225 from the supplied radium.

    These generators set to be dispatched to Fusion Pharmaceuticals’ GMP production facility, have a successful track record in producing various medical isotopes due to their user-friendly nature, negating the need for substantial investments in high-cost cyclotrons and associated infrastructure.

    FUSN has proactively invested in securing the supply of actinium-225 since its inception, establishing a resilient and diversified supply chain. The collaboration with BWXT Medical stands as a pivotal element in Fusion’s strategic approach, as evidenced by the preferred partner agreement announced in January 2023 for the supply of actinium-225.